LearnGlossaryMarketStocksSuperinvestorsSign in

CDXS

Codexis, Inc.

Healthcare · $142M market cap

Verdict

We can't put a fair value on CDXS right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-1.6% a year✗
Sales growth5.3% a year✗
Free cash flow growth—?
Return on invested capital-47.1%✗

Follow CDXS

Track it on your watchlist and see the full analysis. Free.

Create a free account

About Codexis, Inc.

Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works